The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Waldenström macroglobulinemia: Six-year follow-up of phase II trial into front-line BDR in the treatment of newly diagnosed patients
In November 2016, Maria Gavriatopoulou from the National and Kapodistrian University of Athens School of Medicine, Greece, and colleagues published in Blood the results of the six-year follow-up of a multi-center phase II study into the efficacy of chemotherapy-free bortezomib, dexamethasone, and rituximab (BDR) in newly diagnosed WM patients. The study enrolled 59 patients over 10 centers in Europe.
The BDR treatment regimen was 23 weeks long; the first cycle was 21 days with bortezomib IV 1.3mg/m2 on days 1, 4, 8, and 11. Bortezomib was then administered weekly for a further four 35-day cycles at 1.6mg/m2. On cycles 2 and 5, IV dexamethasone and IV rituximab were also delivered at 40mg and 375mg/m2 doses, respectively.
Highlights:
- Majority of patients recruited were intermediate (40%) or high (45.5%) according to IPSSWM
- ITT analysis:
- 85% responded with 3% CR, 7% VGPR, 58% PR, 17% MR
- Major response rate (PR + VGPR + CR) of 68%
- Median PFS: 43 months (with 17% in remission after a median of 90 months)
- 7-year PFS and 7-year OS by risk:
- Low IPSSWM = 62.5% and 87.5%
- Intermediate IPSSWM = 42% and 68.2%
- High IPSSWM = 15% and 48%
- 7-year overall OS = 66%
- Peripheral neuropathy in 46% patients, but this resolved completely or to grade I
The authors concluded by stating that toxicity was mild and that BDR was an active chemotherapy-free treatment, which was shown to result in durable responses over a 6 year follow-up period.
References